ClinicalTrials.gg
RecruitingNCT05961644CLASP-MSUpdated Jul 28, 2023

Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).

A Phase 2/3 interventional study of Cladribine Subcutaneous Injection and 0.9% Chloride Injection Sodium in Multiple Sclerosis, Secondary Progressive and Multiple Sclerosis, sponsored by Institute of Psychiatry and Neurology, Warsaw. Recruiting at 1 site in Poland. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-28.

Sponsored by Institute of Psychiatry and Neurology, Warsaw · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Oct 2022, registered Jul 2023).
  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Multiple Sclerosis, Chronic Progressive with a site in Poland — 5 open to participants now, 11 under way, 9 of them phase 3. Multiple Sclerosis, Chronic Progressive · Poland.

Planned enrollment
22nd of 23
188 · median 769
Started
2022
with 2 others
Phase 2/3
Only one
of the 23
Primary completion
2027-06
later than 5 of 10 live
Registered
18th of 23
by date
Lead sponsor
1 of 23
Institute of Psychiatry and Neurology, Warsaw

Among the 23 studies in Multiple Sclerosis, Chronic Progressive with a site in Poland, this one is the 22nd largest by planned enrollment, is one of 3 that started in 2022, is the only one in phase 2/3, reaches primary completion later than 5 of the 10 other live ones, and was the 18th registered.

Multiple Sclerosis, Chronic Progressive

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

Browse Multiple Sclerosis, Chronic Progressive studies →

Open to participants now

5 of the 23 studies in Multiple Sclerosis, Chronic Progressive with a site in Poland are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.

This study: 30 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Multiple Sclerosis, Chronic Progressive with a site in Poland, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy and safety of subcutaneously administered cladribine versus placebo to stop inflammation and treat disease progression of non-active secondary progressive multiple sclerosis.

Multiple sclerosis is an inflammatory disease of the central nervous system. In most patients, it starts with a relapsing course (RMS) which is caused by acute inflammatory lesions in the brain and spinal cord. RMS transforms at later stages into progressive disease (secondary progressive MS). Currently approved disease-modifying treatments are effective in reducing clinical relapses and brain and spinal lesions visible in MR, but they perform poorly in preventing disease progression and overall disability accumulation. The growing evidence shows that disease progression partially depends on chronic inflammation present in the CNS. Drugs, which may cross the blood-brain barrier and reach inflammatory cells residing in the CNS might be effective in this stage of the disease. Cladribine is one of the DMT approved for RMS. It is a synthetic purine analog with selective lymphocyte toxicity, which enter the CNS and is found in cerebrospinal fluid. In patients treated with cladribine, the oligoclonal bands tend to disappear proving that neuroinflammation is diminished.

The participants of this clinical trial with the later non-active stage of MS are enrolled to be treated with cladribine subcutaneously or a non-active comparator (placebo) for 6 months and followed for the next 2 years, with an MRI scan and clinical evaluation every 6 months. The main questions it aims to answer are if in the non-active stage of MS cladribine is potent to lessen brain volume loss and if it is potent to attenuate inflammation in the CNS.

Read the detailed description

This is a randomized, placebo-controlled, double-blind, multi-center, phase 2 study of subcutaneous cladribine in non-relapsing, secondary progressive multiple sclerosis. Eligible patients will be randomly allocated in a 1:1 ratio to receive either placebo or subcutaneous cladribine at a dose of 1.8 mg/kg of body weight. The study will consist of three periods: screening, treatment, and follow-up. During the screening, the investigators will assess patient eligibility. During the treatment, cladribine will be given over 6 visit every 5-6 weeks. During the follow-up of 96 weeks, safety and efficacy assessments will be carried out on five visits: the first visit will take place 4 weeks after the last cladribine dose, and the remaining visits will take place every 24 weeks.

There will a rescue option of unblinding and treatment with a full dose of cladribine (cladribine arm) or approved medications (placebo arm) for patients with a severe relapse or ≥ 2 non-severe relapses after enrolment or with a substantial neuroimaging disease activity ≥ 4 Gd+ lesions in any scan, ≥ 3 Gd+ lesions in any two scans, ≥ 2 Gd+ lesions in any three scans, or ≥ 9 new/enlarging T2 lesions on any scan compared with baseline).

All raters will be blinded to treatment allocation. All neuroimaging examinations will be evaluated at a central neuroimaging unit by investigators blinded to treatment allocation.

Study type: interventional (clinical trial) Planned enrolment: 188 patients Allocation: randomized Masking: Double (Participant, Investigator) Primary purpose: Treatment Start Date: October 2022

Study design: The study aims to assess the safety and efficacy of subcutaneous cladribine in patients with SPMS who have not experienced relapses over a year and with or without active lesions on neuroimaging. The study will be randomized, placebo-controlled, and double blind. Because no treatment is approved for inactive SPMS, placebo was chosen as the comparator. Patients receiving other treatments for SPMS or immunosuppressant will not be included.

The study will consist of the following phases:

  1. Screening phase (about 4 weeks)
  2. Treatment phase, patients will be randomized 1:1 ratio of either cladribine 1,8mg/kg or placebo (30 weeks)
  3. Follow-up phase , patients will be followed every 24 weeks for up to 122 weeks for safety and efficacy of the treatment;

Patients: The group of 188 patients fulfilling inclusion criteria and not-fulfilling exclusion criteria will enrolled to the study. All patient has to sign written informed consent form approved by Ethics Committee.

Blinding: Randomization and blinding will be done by "dual assessor" approach . Every site will have two teams of blinded and blinded investigators . The blinded investigators include Principal or treating investigators and rating investigators, as well as blinded treating nurse. The unblinded team includes: Randomizing investigator responsible also for laboratory assessment and unblinded nurse/pharmacist responsible for preparing drugs.

Intervention:

Experimental arm Drug: Cladribine at a dose of 1.8 mg/kg of body weight. Cladribine will be given subcutaneously over 6 visits every 5-6 weeks.

Comparator: Placebo matched to the subcutaneous injection of cladribine.

Follow-up: Patients will be assessed and baseline visit, and every 24 weeks over 24 months since the last dose of the interventional drug. The evaluations include:

  1. Medical history, concomitant medication, relapse history
  2. Physical examination, neurological examination
  3. Clinical assessment: EDSS, T25FWT, 9-HPT,
  4. MsQoL and CSSR scale
  5. MRI of head and spinal cord (baseline, every 6 months for head and every 12 months for spinal cord)
  6. Laboratory and biomarkers evaluation (hematology, coagulation, HIV serology, Hepatitis virus B and C serology, tuberculosis tests (Quantiferron test if necessary), ,

The primary end point will be percentage brain volume change between the last dose (week 24) and end of study (week 122). The primary endpoint was selected based on the widely discussed indications for designing studies in the SPMS. The main secondary clinical end points will assess the change in neurological function on the Expanded Disability Status Scale, Timed 25 Foot Walk, and 9-Hole Peg Test, which measures upper limb function. The change in cognitive function will be assessed with various neuropsychological tests. The main secondary neuroimaging end points will include change in the number of contrast-enhancing lesions, the number of T1-hypointesne lesions ("black holes"), and the volume of T2 lesions. The main exploratory end point will be the change in QSM rim+ lesions on brain neuroimaging; these lesions are markers of chronic, smoldering neuroinflammation that may take place behind an intact blood-brain barrier. Change in the concentrations of neurofilament light chain and glial fibrillary acidic protein, which are markers of brain tissue damage, will be main laboratory end points. An exploratory analysis of inflammatory protein biomarkers will be carried out in serum and cerebrospinal fluid of a selected patients (Luminex). The study will assess the safety of cladribine and its effect on quality of life.

The proposed intervention is well supported by the current evidence. Cladribine is among the few drugs that penetrate an intact blood-brain barrier, which allows action on lymphocytes resident in the central nervous system. The study will assess whether cladribine slows down disease progression clinically and it will use the best currently available indicators of disease progression: brain and cervical cord atrophy and the number of demyelinating lesions. Additionally, it will be assessed whether the presence of QSM rim+ lesions is associated with disease course and the therapeutic effect of cladribine. For example, a reduction in the number of these lesions during cladribine treatment would supports an action of the drug behind the blood-brain barrier. An association between QSM rim+ lesions and the therapeutic effect of cladribine could help select a subgroup of patients most likely to benefit from anti-inflammatory treatments. The measurement of serum biomarkers will enable an assessment of the activation of the peripheral immune system (cytokine, chemokines) and of the therapeutic effect of cladribine (NfL, GFAP). The positive results of the current project will allow the design of a phase 3 trial. A practical benefit of the proposed study is that patients with SPSM, who are currently not eligible for any treatment options, will have a choice to receive a potentially effective therapy, which costs substantially less compared to other therapies in MS.

Background: Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating disease of the central nervous system, with about 2.5 million patients worldwide, including 45 thousand in Poland. Most patients have relapsing-remitting MS (RRMS) at the start of the disease, in which neurological symptoms appear during relapses and may subside. There is a dozen of disease-modifying treatments for this form of the disease. Several years after the diagnosis of RRMS, the disease progresses into SPMS, in which disability worsens gradually independently of relapses. Patients with SPMS suffer from restricted mobility (need walking aids, wheelchair), cognitive impairment, (difficulties in workplace and in managing everyday life), depression, pain due to spasticity, chronic fatigue, lack of sphincter control, or sexual dysfunction. These patients need more medical help (office visits, rehabilitation, hospitalization), are more often unemployed, and have a lower quality of life than do patients with RRMS. Currently, three disease-modifying treatments are available for patients with SPMS in Europe: interferon beta-1b (low efficacy), mitoxantrone (serious adverse effects), and siponimod. However, these medications can be used only in patients with active disease, i.e., in those with still observed relapses or active brain lesions on magnetic resonance imaging. Therefore, about a half of patients with SPMS cannot receive any disease-modifying treatment. The current understanding of the pathogenesis of MS suggests that there are two types of neuroinflammation since disease onset. Type-1 neuroinflammation is characterized by an acute, focal infiltration of pathogenic lymphocytes and autoantibodies, which is associated with blood-brain barrier disruption. This type of neuroinflammation may be responsible for relapses and contrast-enhancing lesions. Type-2 neuroinflammation is a chronic, smoldering process that takes place behind a closed blood-brain barrier, and it is characterized by slowly expanding lesions and follicle-like lymph structures in the meninges, and diffuse inflammatory changes in white matter and cortex. Other characteristics of type-2 neuroinflammation include microglial and astroglial activation, delayed maturation of oligodendrocytes, and inhibition of remyelination. These processes cause disease progression independently of relapses. Both types of neuroinflammation occur simultaneously since disease onset, but type-2 neuroinflammation is thought to predominate in the secondary progressive phase. Standard neuroimaging methods cannot pinpoint lesions that are specific for type 2 neuroinflammation, but longitudinal brain atrophy and enlargement of lesions can indirectly measure its magnitude. Quantitative susceptibility mapping (QSM), a new imaging technique, can indicate chronic inflammatory lesions that are surrounded by active microglia at the lesion border. Microglia because of iron load form a hypointense rim, and might be thus shown by QSM technique (rim+ lesions). However, QSM is not currently used in clinical practice it is now recommended for use in clinical trials.

The currently available disease modifying-treatments for SPMS act solely or mainly on type-1 neuroinflammation, and because of that they are approved for patients with relapses or active lesions only. Cladribine is approved for the treatment of RRMS. Cladribine substantially decreases the number of contrast-enhancing lesions and relapse frequency in patients with RRMS (an effect on type-1 neuroinflammation). Cladribine may also act on type-2 neuroinflammation i.e. on the autoreactive lymphocytes resident in the central nervous system, including tertiary lymphoid structures, because cladribine penetrates into the central nervous system through an intact blood-brain barrier. The effect on type-2 neuroinflammation is supported by the observation that oligoclonal bands disappear in patients with RRMS and SPMS after cladribine treatment.

03

Conditions studied

  • Multiple Sclerosis, Secondary Progressive
  • Multiple Sclerosis

Keywords

  • Cladribine
  • Multiple Sclerosis Secondary Progressive
  • Brain Volume
  • Quantitative Susceptibility Mapping
  • Magnetic Resonance Imaging
  • Cognitive assessment
04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Diagnosis of relapse-onset, secondary progressive multiple sclerosis based on the 2017 McDonald criteria
  • Progression of disability over 24 months defined as an increase in the EDSS score of 1 or more for patients with EDSS ≤ 5.5 or of 0.5 or more for patients with EDSS > 5.5
  • Lack of relapses over last 12 months
  • EDSS of 3.5 - 7.5 inclusive
  • Age of 30 - 65 years inclusive
  • Duration of MS of 10 years or longer
  • Pre-menopausal women must refrain from heterosexual intercourse or use a method with a failure rate of \< 1% from enrolment up to 6 months after the last dose of the medicinal product
  • Men must refrain from heterosexual intercourse from enrolment up to 6 months after the last dose of the investigational medicinal product or use a barrier method of contraception, with their female partners using a contraception method with a failure rate of \<1%
  • Able to fulfill all protocol requirements as judged by the investigator

Exclusion criteria

Exclusion Criteria:

  • Lack of written
  • Previous cladribine treatment
  • to the medicinal product
  • Eligible and willing to use interferon beta, siponimod, or mitoxantrone
  • Unable to undergo magnetic resonance imaging
  • Pregnancy or breastfeeding
  • Does not agree to use methods defined above
  • Diseases of the nervous system, such as tumors, stroke, traumatic injury, encephalomyelitis, B12 deficiency, or demyelinating diseases other than multiple sclerosis
  • Major comorbidities, such as cancer, liver failure, kidney failure, heart failure ( II-III), or any other disease that may jeopardize patient safety or make it impossible for the patient to fulfill protocol requirements
  • Relapse within last 12 months
  • Chronic treatment with or (eg, azathioprine, methotrexate, cyclosporine) within last 6 months
  • Disease-modifying treatments for multiple sclerosis (no is required for interferons beta, glatiramer acetate, and dimethyl fumarate; washout of > 6 months for teriflunomide, fingolimod, and natalizumab [an accelerate elimination procedure may be used for teriflunomide instead]; washout of > 12 months for ocrelizumab, mitoxantrone, and alemtuzumab)
  • Relapsing-remitting multiple sclerosis
  • Primary progressive multiple sclerosis
  • or , including detectable HbsA, anti-HBc, or anti-HCV antibodies in serum
  • infection, including a positive screening test (anti-HIV 1/2, protein 24)
  • Active or latent tuberculosis, including a positive result of the QuantiFERON TB Gold test during screening or within 3 months (an inconclusive test must be repeated; two inconclusive tests are taken as a positive result)
  • Other infection that may be worsened by treatment with cladribine
  • Lymphopenia (\< 1000/μl), neutrocytopenia (\< 1500/μl), or thrombocytopenia
  • or aspartate aminotransferase > 2 x (can be repeated when 1.5-3x ULN); Total > 1.5 x ULN (can be repeated when 1.5-3 x ULN); > 9.5 g/dL (can be repeated when 9-9.4 g/dL)
  • Lack of vaccination against COVID-19 - the time from the last dose of a full vaccination regimen is shorter than 6 weeks
  • Any vaccination within last 6 weeks
  • Lack of cancer screening or suspicion of cancer or necessity to carry out additional studies after the following examinations done at screening: chest X-ray in all participants; mammography or breast ultrasound in women; cervical smear in women; prostate-specific antigen in men
  • Patient does not have detectable antibodies against Varicella zoster virus in serum or a proof of two-dose vaccination against this virus (last dose at least 6 months before enrolment)
  • Use of oral or parenteral anticoagulants or antiplatelets other than acetylsalicylic acid
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
188 participants (estimated)

Study arms

  • Experimental
    Experimental

    Drug: Cladribine at a dose of 1.8 mg/kg of body weight. Cladribine will be given subcutaneously over 6 visits every 5-6 weeks.

    Drug: Cladribine Subcutaneous Injection

  • Placebo comparator
    Control

    Comparator: Placebo matched to the subcutaneous injection of cladribine.

    Drug: 0.9% Chloride Injection Sodium

Interventions

  • DrugCladribineStudies of CladribineCladribine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cladribine subcutaneous injection, 10 mg daily, for 2-3 consecutive days (depending on individual dose)

    Also known as: Cladribine Solution

  • Drug0.9% Chloride Injection Sodium

    0.9% sodium chloride injected subcutaneously, 10 ml daily, for 2-3 consecutive days

06

What researchers measure

Primary outcomes

  1. Percent brain volume

    brain volume to total intracranial volume

    Time frame: 26 week following baseline

  2. Percent brain volume

    brain volume to total intracranial volume

    Time frame: 122 week following baseline

Secondary outcomes

  1. 24 weeks confirmed composite progression of disability

    Time to 24-week confirmed composite progression of disability defined as the occurrence of any of the following events: (1) an increase in the EDSS score of 1 or greater in patients with baseline EDSS ≤ 5.5 or of 0.5 or greater in those with baseline EDSS \> 5.5; (2) an increase of 20% or more in Timed 25-Foot Walk; (3) an increase of 20% or more in the 9-Hole Peg Test.

    Time frame: 96 week

  2. Symbol-Digit Modality Test

    Cognitive performance assessed with Symbol-Digit Modality Test

    Time frame: 26 week

  3. Symbol-Digit Modality Test

    Cognitive performance assessed with Symbol-Digit Modality Test

    Time frame: 96 week

  4. California Verbal Learning Test

    Cognitive performance assessed with California Verbal Learning Test \[Polish version 2010\]

    Time frame: 26 week

  5. California Verbal Learning Test

    Cognitive performance assessed with California Verbal Learning Test \[Polish version 2010\]

    Time frame: 122 week

  6. Multiple Sclerosis Quality of Life Questionnaire 54 [MSQOL-54]

    The MSQOL-54 is a structured, self-report questionnaire filled by the patient.The 54-item instrument generates 12 subscales along with two summary scores, and two additional single-item measures. The summary scores are the physical health composite summary and the mental health composite summary, each may achieve final score from 0 to 100 points.

    Time frame: 26 week

  7. Multiple Sclerosis Quality of Life Questionnaire 54 [MSQOL-54]

    The MSQOL-54 is a structured, self-report questionnaire filled by the patient.The 54-item instrument generates 12 subscales along with two summary scores, and two additional single-item measures. The summary scores are the physical health composite summary and the mental health composite summary, each may achieve final score from 0 to 100 points.

    Time frame: 122 week

  8. Assessment of disease activity in MRI

    Number of Gd+ lesions Number of new/enlarging T2 lesions

    Time frame: 96 week

  9. Assesment of chronic inflammation in MRI

    Number of QSM rim+ lesions

    Time frame: 96 week

  10. Volume change of cervical spine

    Volume of cervical spinal cord in T1

    Time frame: 96 week

  11. Laboratory measures -neurofilament light chain serum level

    Concentration of neurofilament light chain in serum

    Time frame: 0 to 122 week

  12. Laboratory measures

    Concentration of GFAP in serum

    Time frame: 0 to 122 week

  13. Laboratory measures - pro-inflammatory cytokines

    Concentration of cytokines in serum

    Time frame: 0 to 122 week

  14. Oligoclonal bands (OCB)

    Presence of oligoclonal bands in cerebrospinal fluid (selected patients who will sign an additional consent)

    Time frame: 0 to 122 week

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Lassmann H. Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis. Front Immunol. 2019 Jan 10;9:3116. doi: 10.3389/fimmu.2018.03116. eCollection 2018. PubMed 30687321 ↗
  • Jamroz-Wisniewska A, Beltowski J, Wojcicka G, Bartosik-Psujek H, Rejdak K. Cladribine Treatment Improved Homocysteine Metabolism and Increased Total Serum Antioxidant Activity in Secondary Progressive Multiple Sclerosis Patients. Oxid Med Cell Longev. 2020 Mar 14;2020:1654754. doi: 10.1155/2020/1654754. eCollection 2020. PubMed 32256946 ↗
  • Fox RJ, Chataway J. Advancing trial design in progressive multiple sclerosis. Mult Scler. 2017 Oct;23(12):1573-1578. doi: 10.1177/1352458517729768. PubMed 29041871 ↗
  • Meinl E, Krumbholz M, Derfuss T, Junker A, Hohlfeld R. Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis. J Neurol Sci. 2008 Nov 15;274(1-2):42-4. doi: 10.1016/j.jns.2008.06.032. Epub 2008 Aug 19. PubMed 18715571 ↗
  • Montalban X, Belachew S, Wolinsky JS. Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis. N Engl J Med. 2017 Apr 27;376(17):1694. doi: 10.1056/NEJMc1702076. No abstract available. PubMed 28445663 ↗
  • Comi G, Cook S, Giovannoni G, Rieckmann P, Sorensen PS, Vermersch P, Galazka A, Nolting A, Hicking C, Dangond F. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2019 Apr;29:168-174. doi: 10.1016/j.msard.2019.01.038. Epub 2019 Jan 24. PubMed 30885375 ↗
  • Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet. 1997 Feb;32(2):120-31. doi: 10.2165/00003088-199732020-00003. PubMed 9068927 ↗
  • Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet. 1994 Jul 2;344(8914):9-13. doi: 10.1016/s0140-6736(94)91046-4. PubMed 7912347 ↗
  • Rejdak K, Stelmasiak Z, Grieb P. Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study. Mult Scler Relat Disord. 2019 Jan;27:117-120. doi: 10.1016/j.msard.2018.10.006. Epub 2018 Oct 10. PubMed 30368223 ↗
  • Jorgensen LO, Hyrlov KH, Elkjaer ML, Weber AB, Pedersen AE, Svenningsen AF, Illes Z. Cladribine modifies functional properties of microglia. Clin Exp Immunol. 2020 Sep;201(3):328-340. doi: 10.1111/cei.13473. Epub 2020 Jul 6. PubMed 32492189 ↗
  • Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20. Erratum In: Mult Scler. 2020 Apr;26(4):517. doi: 10.1177/1352458520906383. PubMed 29353550 ↗
  • Frischer JM, Weigand SD, Guo Y, Kale N, Parisi JE, Pirko I, Mandrekar J, Bramow S, Metz I, Bruck W, Lassmann H, Lucchinetti CF. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015 Nov;78(5):710-21. doi: 10.1002/ana.24497. Epub 2015 Aug 24. PubMed 26239536 ↗
  • Hametner S, Wimmer I, Haider L, Pfeifenbring S, Bruck W, Lassmann H. Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol. 2013 Dec;74(6):848-61. doi: 10.1002/ana.23974. Epub 2013 Oct 7. PubMed 23868451 ↗
  • Dal-Bianco A, Grabner G, Kronnerwetter C, Weber M, Hoftberger R, Berger T, Auff E, Leutmezer F, Trattnig S, Lassmann H, Bagnato F, Hametner S. Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging. Acta Neuropathol. 2017 Jan;133(1):25-42. doi: 10.1007/s00401-016-1636-z. Epub 2016 Oct 27. PubMed 27796537 ↗
  • Absinta M, Sati P, Masuzzo F, Nair G, Sethi V, Kolb H, Ohayon J, Wu T, Cortese ICM, Reich DS. Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo. JAMA Neurol. 2019 Dec 1;76(12):1474-1483. doi: 10.1001/jamaneurol.2019.2399. Erratum In: JAMA Neurol. 2019 Dec 1;76(12):1520. doi: 10.1001/jamaneurol.2019.4331. PubMed 31403674 ↗
  • Kaunzner UW, Kang Y, Zhang S, Morris E, Yao Y, Pandya S, Hurtado Rua SM, Park C, Gillen KM, Nguyen TD, Wang Y, Pitt D, Gauthier SA. Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions. Brain. 2019 Jan 1;142(1):133-145. doi: 10.1093/brain/awy296. PubMed 30561514 ↗
  • Elliott C, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, Bernasconi C, Wei W, Belachew S, Arnold DL. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Mult Scler. 2019 Dec;25(14):1915-1925. doi: 10.1177/1352458518814117. Epub 2018 Dec 19. PubMed 30566027 ↗
  • Wang CT, Barnett M, Barnett Y. Imaging the multiple sclerosis lesion: insights into pathogenesis, progression and repair. Curr Opin Neurol. 2019 Jun;32(3):338-345. doi: 10.1097/WCO.0000000000000698. PubMed 30950846 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Jun 2027, 56 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2023
First posted
Jul 27, 2023
StartActual
Oct 3, 2022
Primary completionEst.
Jun 30, 2027
CompletionEst.
Oct 30, 2027
Last update
Jul 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05961644
Lead sponsor
Institute of Psychiatry and Neurology, Warsaw
Collaborators
Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, Mossakowski Medical Research Centre Polish Academy of Sciences, Poznan University of Medical Sciences, Military Institute of Aviation Medicine
Responsible party
Sponsor
First posted
Jul 27, 2023
Start date
Oct 3, 2022
Primary completion
Jun 30, 2027 (estimated)
Completion
Oct 30, 2027 (estimated)
Last update
Jul 28, 2023

Study contacts

Iwona Kurkowska-Jastrzebska, MD, PhD
Contact
ikurkowska@ipin.edu.pl
+48-4582800 ext. 557
Łukasz Smolinski, MD, PhD
Contact
lsmolinski@ipin.edu.pl
+48-4582800 ext. 601
Iwona Kurkowska-Jastrzebska, MD, PhD
principal investigator · Institute for Psychiatry and Neurology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cladribine

Start the discussion